Last reviewed · How we verify
Intermediate dose thromboprophylaxis
Intermediate dose thromboprophylaxis uses anticoagulants at moderate doses to prevent blood clot formation in patients at intermediate risk.
Intermediate dose thromboprophylaxis uses anticoagulants at moderate doses to prevent blood clot formation in patients at intermediate risk of thrombotic events. Used for Thromboprophylaxis in intermediate-risk surgical or medical patients, Prevention of venous thromboembolism in hospitalized patients at moderate risk.
At a glance
| Generic name | Intermediate dose thromboprophylaxis |
|---|---|
| Also known as | intermediate dose Enoxaparin |
| Sponsor | UMC Utrecht |
| Drug class | Anticoagulant (dosing strategy) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This is a dosing strategy rather than a specific drug, employing anticoagulants (typically low-molecular-weight heparins or fondaparinux) at intermediate therapeutic levels to balance thrombotic and bleeding risks. It is commonly used in hospitalized patients, those undergoing surgery, or those with conditions like acute medical illness or cancer where standard prophylactic doses may be insufficient but full therapeutic anticoagulation is not yet indicated.
Approved indications
- Thromboembolism prevention in hospitalized patients at intermediate risk
- Perioperative thromboprophylaxis in intermediate-risk surgical patients
- Thromboembolism prevention in acute medical illness
- Cancer-associated thrombosis prevention
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
- Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
- Prolonged Hypercoagulability Following Major Liver Resection for Malignancy (PHASE3)
- Pregnancy and Risk of Venous Thromboembolism (NA)
- Covid-19 Associated Coagulopathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |